A ‘catch and kill’ mask that offers to get us back to work, welcome SINTX

A classic story of repurposing your tried and true Intellectual Property, allow me to introduce you to SINTX Technologies, Inc. (NASDAQ: SINT). SINTX is a leading manufacturer of silicon nitride which is a very hard, abrasion- and corrosion-resistant ceramic solid that’s inherently antibacterial and antiviral. These last two factors have caused the company to create quite a stir in this new world of COVID-19.

But first, let’s take a step back and look at how this company got started. Way back in 1996 the company was developing a ceramic hip replacement system. From there they launched multiple new silicon nitride spinal implants gaining regulatory clearances in Europe, Brazil, and Australia. Today their devices are used in over 35,000 human spine implantations.

From there they diversified their product line into more industrial applications such that they are now involved in aerospace, bearings, and drilling. In October 2020 they received the AS9100D certification for the Aerospace Quality Management System, meaning that SINTX equipment now meets the stringent standards of the aerospace industry thus achieving a critical step in entering the aviation, space, and defense market sectors. Of note, they have a 30,000 sq. ft., state-of-the-art manufacturing facility (and headquarters) in Salt Lake City which is FDA registered and ISO certified.

When it comes to Silicon nitride this team and their R&D is second to none. They have over 130 peer-reviewed scientific publications, more than 85 technical and scientific presentations and 12 Patents issued with another 56 Patent applications. So when COVID-19 came along they were able to improvise and adapt to develop yet another product line to add to the mix. In October 2020 (apparently a good month for the company) the SINTX R&D team bonded silicon nitride particles consistently and evenly into the fibers of a nonwoven fabric layer, in an effort to manufacture a “catch and kill” face mask that will inactivate respiratory viruses. That’s a bit of a mouthful but essentially they found that their silicon nitride inactivated the SARS-CoV-2 virus upon contact.

And that brings us to yesterday when the company press released confirmation of results on tests done at the University of Rochester, New York, which show that fabrics containing silicon nitride had comparable efficacy against inactivation of the SARS-CoV-2 virus to what their R&D team initially discovered. This opens up a whole new, and potentially highly profitable, business to SINTX. In addition to the “catch and kill” face mask, the Company expects the antiviral fabrics could be used in many applications, such as surgical gowns and drapes, automotive and HVAC filters, wound dressings, clothing, and more. SINTX believes that products made of its fabrics will inactivate trapped pathogens and reduce the risk of disease transmission. Effective HVAC filters would be a huge step in getting people back into offices and back on to cruise liners and into airplanes.

If you think all this is pretty interesting stuff, then you’ll really like the fact that this company has no debt, over US$20 million in cash and ONLY 26.1 million shares outstanding on a fully diluted basis. So despite their 50+% rally in this latest news, the market cap of this intriguing company is still under US$50 million. Granted they aren’t profitable yet, and COVID-19 negatively impacted their spinal implant business. Nevertheless, as they found one door closing it definitely opened up a new door for SINTX to show off their innovative spirit.

XPhyto Therapeutics Hugh Rogers on the fastest and most portable PCR test available

In a recent InvestorIntel interview, Peter Clausi spoke with Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY | OTCQB: XPHYF) about XPhyto’s rapid point-of-care COVID-19 PCR test system which is very close to commercialization.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Hugh went on to speak on the different types of COVID-19 tests out of which, he said, “PCR test is the gold standard of diagnostics.” He added that XPhyto’s PCR test is less invasive as it is oral and requires minimal equipment and training. The test has been optimized for speed and portability. “What we have designed is we believe to be the fastest and most portable PCR test available…”

To watch the full interview, click here

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

To learn more about XPhyto Therapeutics Corp., click here

Disclaimer: XPhyto Therapeutics Corp. is an advertorial member of InvestorIntel Corp.

Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio

COVID-19 continues to be a huge global problem with global cases now over 112 million. Vaccines are a source of hope but just as valuable are treatments that can help infected COVID-19 patients before they become another horrific statistic.

One specialty pharmaceutical company has a potential anti-COVID-19 product currently in the clinical trial phase. That company is Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF | FSE: VP2) (‘Valeo’).

Valeo has an anti-COVID-19 product currently in a clinical trial known as the Hesperidin Coronavirus Study. Valeo Pharma’s Hesperco™ capsules are Health Canada approved (for immune support) and are at the core of Montreal Heart Institute’s Hesperidin Coronavirus Clinical Trial. HesperCo™ is Valeo’s unique hesperidin formulation. Hesperidin is a flavonoid with powerful antioxidant properties that helps support the immune system, and may potentially help in the fight against COVID-19.

Valeo Pharma and Ingenew Pharma are trialing their Hesperco™ flavonoid product in the fight against COVID-19

Valeo states: “Hesperidin interferes/ inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunity. Hesperidin’s safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process……hesperidin, the medicinal ingredient contained in HESPERCO™ capsules, and its efficacy against other coronavirus strains are well documented in scientific literature….”

Note: Bold emphasis by the author.

‘Inhibiting COVID-19 entry into our cells’ and ‘boosting immunity’. Wow! This could potentially be a game-changer if successful. With the world currently at 112,654,202 confirmed COVID-19 cases and 2,496,749 COVID-19 deaths (as of February 24, 2021), a product that can inhibit COVID-19 while at the same time boosting our immunity would be an incredible breakthrough.

Valeo’s HESPERCO™ development partner is Ingenew Pharma. Ingenew’s President & CEO stated: “Although hesperidin can be found in lower concentration in citrus fruits or some natural health products, a much higher hesperidin concentration, such as the one found in Hesperco™, is required to achieve therapeutic benefits…With its well-documented anti-inflammatory and anti-oxidant activity, hesperidin may also provide further protection to the infected subjects by reducing the COVID-19-induced cytokine storm (severe inflammatory response) observed in severe cases.”

Valeo Pharma is focusing on specialty products to fight neurodegenerative diseases, cancers, pain, and maybe COVID-19

About Valeo Pharma Inc.

Valeo’s business plan is to become a leading Canadian-focused specialty pharmaceutical company and be the partner of choice for international companies wishing to enter the Canadian market. Valeo’s focus is mostly on specialty areas such as neurodegenerative diseases (MS, Parkinson’s, and Schizophrenia), oncology (cancer) and supportive care/pain management, and hospital specialty products.

Valeo partners with pharmaceutical companies that have expertise in research & development and manufacturing while Valeo concentrates on the regulatory requirements to get a drug approved in Canada and then focuses on marketing the product. Valeo state: “Our focus is getting the product on the market, and we have all the capabilities in-house to register and commercialize innovative pharmaceuticals in Canada.”

Valeo currently has 10 products in their portfolio with another 3 in the pipeline.

Valeo’s revenue is forecast to triple from FY2020 revenue of C$8.0 million to a forecast FY2021 revenue of C$24.0 million.

Closing remarks

Valeo Pharma Inc. trades on a market cap of C$68 million which seems rather small when we look at much larger pharmaceutical companies such as Pfizer Inc. on a market cap of US$188 billion. Sure they are not comparable companies in terms of current products, revenues etc; but it does highlight the potential size to which the most successful pharmaceutical companies can grow. If we compare to the successful natural vitamin companies such as Blackmores, it trades on a market cap of A$1.53 billion.

Valeo’s strategy to partner with other product developers means they can reduce R&D expenses, time to market, and focus on marketing & sales. This is a quicker and smarter way to achieve revenues. Valeo’s stock is up 128% over the past year so it certainly looks like their strategy is working.

Valeo Pharma’s Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19

In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF) about Valeo’s recent news release on the use of its Hesperco™ Capsules at the Core of Montreal Heart Institute’s Hesperidin Coronavirus Clinical Trial.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Steve went on to say “Hesperidin is a natural product with very good safety profile and potential efficacy.” The Montreal Heart Institute is a leading institute that has done a number of trials. Steve commented that for them to be interested in Hesperidin is testament to the many hours of research “…demonstrating that Hesperidin could have a very positive effect on patients that are symptomatic with COVID-19.”

Steve also provided an update on the commercial launch of Redesca™ which is a biosimilar used as a blood thinner. He said that the drug has “great market potential” and has recently received a positive recommendation for public reimbursement in Quebec. The company expects to launch the product in early May. “Our revenues are slated to almost triple in the current fiscal year which ends October 21st,” Steve commented.

To watch the full interview, click here

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., click here

Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

StageZero on revenues being generated via testing operations, partners and a status report on the Aristotle test

In a recent InvestorIntel interview, Tracy Weslosky speaks with James Howard-Tripp, Chairman and CEO of StageZero Life Sciences Ltd. (TSX: SZLS) about an update on StageZero’s Aristotle test. This test, which can simultaneously screen for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer, was one of numerous discussions they had in this interview.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), James went on to say that StageZero is on track and continues to advance towards the launch of its Aristotle® test. He further said that StageZero has generated revenues with it’s COVID-19 testing operations which continues to grow every quarter. “We think COVID revenue is going to continue for a while…it should get eclipsed by Aristotle® when Aristotle® comes forward,” He said. “We are two and half time bigger now than we were in March last year.”

Speaking on StageZero’s Virtual COVID-19 PCR Testing Program James said, “We have partnered with Ichor and Air Canada to equip the passengers, when they leave, with kits to allow them get tested while they were away and get back again.”

To watch the complete interview, click here

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (swab) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phle1.7botomist who can prescribe and draw samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.

To know more about StageZero Life Sciences Ltd., click here

Disclaimer: StageZero Life Sciences Ltd. is an advertorial member of InvestorIntel Corp.

Fever detection system sales driving Predictiv AI’s revenue higher

This week, Predictiv AI Inc. (TSXV: PAI) reported that its channel reseller in Quebec and Atlantic Canada, KleinCity Group, secured orders for Predictiv AI’s ThermalPass fever-detection system from hospitals and long-term care facilities in the province of Quebec.

KleinCity expects to close more ThermalPass sales based on the high volume of inbound calls and written requests it has recorded.

Last week, Predictiv AI announced that it received 28 orders for ThermalPass units with installations scheduled before the end of year. The majority of these units were sold to a Canadian provincial government, U.S. public schools, and several hospitals.

Michael Lende, President and CEO of Predictiv AI remarked, “We are very excited with the initial bookings as they represent verticals that are innately scalable. We are also cognizant and encouraged that these orders are formative in nature and have the potential to be significantly upsized.”

In conjunction with these recent sales and pending orders, production and assembly of ThermalPass units are ramping up, and the Company plans to expand manufacturing capacity to meet the increased demand.  Predictiv AI is well funded for growth after closing a $1.5 million financing in October.

Thermalpass to Help Food Bank Prioritize Health of its Residents

In the holiday spirit, Predictiv AI donated one of its ThermalPass fever detection systems to the Flemingdon Food Bank in Toronto, Canada.

As the demand for food banks continues to increase amid this current health crisis and busy holiday season, the ThermalPass unit will help keep patrons, staff, and volunteers, healthy and safe.

ThermalPass Fever Detection System

In May, Predictiv AI launched ThermalPass, a fever-detection system that instantly screens for higher than normal body temperatures that could be caused by influenza, pneumonia or other viruses, such as COVID-19.

ThermalPass enhances public safety by providing fast, touch-free scanning of people at entranceways of high-traffic, public locations to reduce the risk of spreading COVID-19 and other fever-bearing contagions.

By integrating 24 medical-grade, non-invasive thermal sensors onto a metal frame, and taking 1200 readings per second, each unit can process 60 people per minute. Its waterproof design is flexible for both indoor and outdoor uses.

A primary factor driving the growth of this market includes increasing demand for mass screening at airports, hospitals, malls, office buildings, pharmacies, schools, stadiums and supermarkets.

Other solutions that use thermal cameras, come with privacy issues and are more expensive, costing as much as US$15,000 compared with ThermalPass Portable (US$6,900) or ThermalPass Pro (US$7,300).

In addition to the upfront hardware sale of the product, Predictiv AI also books monthly recurring revenue (“MRR”) from maintenance & services fees, and monetizes the aggregated data.

Global Thermal Scanners Market is a Billion Dollar Market and Growing

According to a recent report by Reportlinker, the Global Thermal Scanners Market size is expected to reach $6.7 billion by 2025, rising at an annual growth rate of over 10%.

Even with the COVID-19 vaccines roll-out, the general public is poised to adopt new safety measures to protect society from current and future infectious diseases. For example, in the province of Ontario, under the province’s Stage 3 regulations, employers are required to conduct employee screening for COVID-19 whenever an employee comes to work.

A short-term catalyst for the market was a notice in July from the US government banning Chinese-based thermal camera solutions over privacy and national security issues. These cameras need to removed by August 2021.

Predictiv AI – Not a 1-Product Company

Based in Toronto, Canada, Predictiv AI is a strategic investor and operator of emerging technology companies with a focus on Internet of Things (“IoT”), artificial intelligence (“AI”) and Blockchain solutions.

The Company’s R&D division, AI Labs Inc., develops new products to solve real-world business problems. AI Labs jointly developed ThermalPass with Commersive Solutions, a developer of integrated, point-of-sale technologies for the retail market.

Predictiv AI’s Weather Telematics (“WTX”) subsidiary uses patented monitoring sensors to provide real-time, advanced AI-based, predictive road condition weather risk information to the insurance, logistics, fleet management and public safety sectors. In May, WTX released Alert Fleet, a weather-based software solution to enhance safety and reduce costs for the North American Fleet Management market.

Predictiv AI helps businesses and organizations make smarter decisions using AI, deep machine learning and data science.

With a market capitalization of less than $15 million, there is still plenty of upside to this Canadian high-tech company.

ThermalPass Series of Fever Detection systems

Valeo Pharma’s approval and launch of immune support product line Redesca and Redesca HP anticipated to impact first half 2021 revenue

Most investors know that the pharmaceutical industry is a huge and mostly very profitable industry. What they may not know is that it is highly competitive making it hard for new players to break into the sector. One way to do that is to have a specialty focus; another is to bring a new drug to market at the right time. Right now immune support products are a hot sector as coronavirus (COVID-19) continues to ravage the world. A

Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF) (‘Valeo’) has a specialty pharmaceuticals focus and their newly launched immune support product HesperCo™ looks like being a possible winner as we all look to boost our immune systems to prevent or fight COVID-19. HesperCo™ is Valeo’s unique hesperidin formulation. Natural product hesperidin is a flavonoid with powerful antioxidant properties that help support the immune system.

In a September 2020 news release Valeo stated: “We have high expectations for HesperCo™, which will be launched nationally in the coming weeks, as the immune support it provides is needed in the current healthcare environment.” Since this press release HesperCo™ has been launched.

Valeo Pharma’s latest product HesperCo™ is an immune support medicine that may potentially prove useful in the fight against COVID-19


Other new Valeo products that have been launched recently – Yondelis, Ametop Gel, Ethacrynate Sodium and soon Amikacin & Redesca

  • Yondelis – An anti-neoplastic (anti-cancer) agent that aims to prevent, inhibit or halt the development of a neoplasm (cancerous growth). Clearly this is a hugely needed and important area.
  • Ametop Gel – A topical analgesic used for local anaesthetic prior to venepuncture.
  • Ethacrynate Sodium – A saluretic-diuretic agent that is useful to support Nephrotic Syndrome (a kidney disease that causes patients to pass too much protein in their urine). Commercialization has just begun in the U.S.
  • Amikacin – A specialty hospital antibiotic. Valeo has recently received Health Canada approval with commercialization to start in the first half of 2021.
  • Redesca and Redesca HP – Valeo has just announced yesterday that they received Health Canada approval for Redesca and Redesca HP (low molecular weight heparin biosimilars). Low molecular weight heparin is increasingly used to prevent serious COVID-19 complications such as thrombosis (blood clots) and pulmonary embolism. Valeo says that commercial launch of Redesca and Redesca HP will impact first half 2021 revenue and is forecast to achieve $30 million annual peak sales.

More about Valeo Pharma

Valeo’s strategy is to focus on specialty areas such as neurodegenerative diseases, oncology, and hospital specialty products. Valeo is focused on those therapeutic fields where a relatively small number of general practitioners or specialist physicians account for the majority of prescriptions written. This can be a more effective strategy to gain success, especially for smaller pharma companies.

Valeo Pharma is driven by the desire to become a leading Canadian focused specialty pharmaceutical company and to be the partner of choice for international companies wishing to enter the Canadian market.

Valeo had a productive Q3, 2020 with 4 new products added to their commercial pipeline. Q3 net revenues were C$1.5 million and YTD 2020 net revenues were C$5.3 million.

Valeo Pharma’s product portfolio and product pipeline


Valeo Pharma’s revenue is forecast to grow very strongly through to 2022

Source: 4-traders

Closing remarks

Specialty pharma in the areas of infectious disease (think COVID-19), oncology (cancer), neuro-degenerative diseases (think nerve diseases), and hospital specialty products all look to be areas of strong future demand.

Valeo Pharma is focusing on these high growth specialty areas in Canada. As a result of past products and several recent new product launches Valeo’s revenue is forecast to increase sharply in the next 2 years. The current market cap is C$74 million.